Near complete pathologic response to PD-1 inhibitor and radiotherapy in a patient with locally advanced pancreatic ductal adenocarcinoma

Patrick M. McCarthy*, Matthew J. Rendo, Matthew D. Uy, Alexandra M. Adams, Anne E. O’Shea, Daniel William Nelson, Joshua L. Fenderson, Katherine M. Cebe, Robert W. Krell, Guy T. Clifton, George E. Peoples, Timothy J. Vreeland

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains deadly despite advances in systemic therapies and surgical techniques. While there is increasing utilization of immune therapies across diverse cancer types, PDAC remains generally resistant to these treatments. We report a case of locally advanced PDAC treated with preoperative radiation and anti-PD-1 immunotherapy guided by preoperative PD-L1 tumor analysis. After 4 months of preoperative therapy, the patient was submitted to resection, demonstrating a near-complete pathologic response on final tumor analysis. We will discuss the relevant literature and current state of immunotherapeutics for PDAC.

Original languageEnglish
Pages (from-to)3537-3544
Number of pages8
JournalOncoTargets and Therapy
Volume14
DOIs
StatePublished - 2021
Externally publishedYes

Keywords

  • Complete response
  • Immune checkpoint inhibitor
  • Locally advanced
  • PD-L1
  • Pancreatic cancer
  • Pembrolizumab

Fingerprint

Dive into the research topics of 'Near complete pathologic response to PD-1 inhibitor and radiotherapy in a patient with locally advanced pancreatic ductal adenocarcinoma'. Together they form a unique fingerprint.

Cite this